Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well saracatinib works in treating patients with
previously treated metastatic pancreatic cancer. Saracatinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.